bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections. This strategic acquisition aims to enhance bioMérieux’s capabilities in next-generation sequencing (NGS) and rapid diagnostics, further solidifying its commitment to advancing healthcare and Antimicrobial Stewardship through innovative solutions. Day Zero Diagnostics has developed groundbreaking technologies that integrate direct-from-whole-blood sample preparation, sequencing, and advanced ID/AST analytics.
Read the full article: bioMérieux Strengthens Its Next-Generation Sequencing Capabilities with the Acquisition of Day Zero Diagnostics Solutions and Technologies //
Source: https://www.biomerieux.com/corp/en/journalists/press-releases/NGS-sequencing-acquisition-day-zero-diagnostics.html